Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
Domain	F-box	FBXO47 FBXL4	5.51e-03	67	31	2	PF00646
Domain	FBOX	FBXO47 FBXL4	6.34e-03	72	31	2	PS50181
Domain	F-box_dom	FBXO47 FBXL4	6.86e-03	75	31	2	IPR001810
Pubmed	Direct interaction between hnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice.	MAP2K4 USP39 ATR SUPV3L1 ARCN1 CPNE3	1.10e-05	582	31	6	20467437
Pubmed	The cell proliferation antigen Ki-67 organises heterochromatin.	UTP18 USP39 ATR VPS53 ARCN1	2.93e-05	410	31	5	26949251
Pubmed	ARHGAP24 represses β-catenin transactivation-induced invasiveness in hepatocellular carcinoma mainly by acting as a GTPase-independent scaffold.	UTP18 USP39 VPS53 FOXK1 CPNE3	4.61e-05	451	31	5	36168627
Pubmed	Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis.	MAP2K4 EPHB1	9.16e-05	16	31	2	8755474
Pubmed	Neither replication nor simulation supports a role for the axon guidance pathway in the genetics of Parkinson's disease.	MRAS EPHB1	1.76e-04	22	31	2	18628988
Pubmed	Mouse screen reveals multiple new genes underlying mouse and human hearing loss.	CYP3A5 VPS53 FBXO47 SUPV3L1 PABIR3 DDHD1	7.01e-04	1242	31	6	30973865
Cytoband	17q21.33	UTP18 ACSF2	3.56e-04	41	31	2	17q21.33
Cytoband	Ensembl 112 genes in cytogenetic band chr3q22	MRAS EPHB1	3.77e-03	135	31	2	chr3q22
Cytoband	Ensembl 112 genes in cytogenetic band chr8q22	RGS22 AZIN1	5.77e-03	168	31	2	chr8q22
Drug	Telazol	CYP3A5 EPHB1	6.42e-05	9	31	2	CID000062270
Drug	f-Pt	MAP2K4 MRAS CYP3A5	9.43e-05	65	31	3	CID003000505
Drug	MMEA	MAP2K4 CYP3A5	9.79e-05	11	31	2	CID000125823
Drug	3'-hydroxyacetanilide	MAP2K4 CYP3A5	2.41e-04	17	31	2	CID000012124
Drug	lonafarnib	MAP2K4 MRAS CYP3A5	6.34e-04	124	31	3	CID000148195
Drug	BDCM	MRAS CYP3A5	7.12e-04	29	31	2	CID000006359
Drug	B Ba	AZIN1 EPHB1	7.12e-04	29	31	2	CID000001499
Drug	aflatoxin G1	ATR CYP3A5	8.68e-04	32	31	2	ctd:C027955
Drug	KMBA	CYP3A5 AZIN1	9.80e-04	34	31	2	CID000000473
Drug	fipronil	MRAS ATR CYP3A5 DISP1 FBXL4	1.18e-03	597	31	5	ctd:C082360
Drug	NSC325611	MAP2K4 CYP3A5	1.29e-03	39	31	2	CID000003239
Drug	amodiaquine	CYP3A5 AZIN1	1.36e-03	40	31	2	CID000002165
Disease	Squamous cell carcinoma of lung	MAP2K4 ATR	4.86e-04	32	30	2	C0149782
Disease	executive function measurement, unipolar depression, cognitive function measurement	SYT4 DCAF6	1.24e-03	51	30	2	EFO_0003761, EFO_0008354, EFO_0009332
Disease	body weight	ZNF521 SYT4 MRAS UTP18 RTTN EPHB1	1.48e-03	1261	30	6	EFO_0004338
Disease	lung cancer (is_implicated_in)	MAP2K4 ATR	2.58e-03	74	30	2	DOID:1324 (is_implicated_in)
Disease	respiratory symptom measurement, COVID-19	SYT4 RGS22	2.58e-03	74	30	2	EFO_0007939, MONDO_0100096
Disease	neuroimaging measurement, brain volume measurement	ZNF521 ATR DRAM1	3.01e-03	286	30	3	EFO_0004346, EFO_0006930
Disease	daytime rest measurement	ZNF521 MRAS EPHB1	3.29e-03	295	30	3	EFO_0007828
Disease	Prostatic Neoplasms	DCAF6 ATR CYP3A5 CPNE3	3.35e-03	616	30	4	C0033578
Disease	Malignant neoplasm of prostate	DCAF6 ATR CYP3A5 CPNE3	3.35e-03	616	30	4	C0376358
Disease	response to anticonvulsant	ZNF521 DISP1	3.39e-03	85	30	2	GO_0036277
Disease	physical activity	ZNF521 FBXO47	3.62e-03	88	30	2	EFO_0003940
Disease	Ischemic stroke	XKR9 EFCAB12 EPHB1	4.28e-03	324	30	3	HP_0002140
Disease	facial width measurement	DISP1 FOXK1	5.11e-03	105	30	2	EFO_0007855
Disease	pancreatic cancer (is_implicated_in)	MAP2K4 ATR	5.79e-03	112	30	2	DOID:1793 (is_implicated_in)
Disease	mood instability measurement	FOXK1 EPHB1	7.50e-03	128	30	2	EFO_0008475
Disease	hemorrhoid	MAP2K4 XKR9	9.79e-03	147	30	2	EFO_0009552
Disease	insomnia, total blood protein measurement	OR4K17 DDHD1	9.91e-03	148	30	2	EFO_0004536, EFO_0004698
Disease	apolipoprotein A 1 measurement	SYT4 VPS53 FOXK1 AZIN1	1.02e-02	848	30	4	EFO_0004614

Protein segments in the cluster

Peptide	Gene	Start	Entry
KNFITCFKDPQFLVT	C8orf82	61	Q6P1X6
MKNFFFVPSCIQLSQ	AZIN1	426	O14977
IRVLQNFSFKPCKET	CYP3A5	456	P20815
IKNCLNPQFSKTFII	CPNE3	51	O75131
GCKALVFPKQFKTQQ	ACSF2	171	Q96CM8
NIFSAKFLPCTNDKQ	DCAF6	96	Q58WW2
IFTCFKKPQQQIYDN	DISP1	666	Q96F81
PVIAHCFKQFQQKDF	EFCAB12	36	Q6NXP0
FSPSFINFVNLCLTK	MAP2K4	336	P45985
KSALTIQFFQKIFVP	MRAS	26	O14807
NINQKRFSKAQPTCF	PABIR3	121	Q6P4D5
KIVQKQNQTCYFSTP	DRAM1	76	Q8N682
VFFKKCPSIVQNFAV	EPHB1	191	P54762
CQHVFVLKTFFPQKV	GTSF1L	111	Q9H1H1
KQKVISFAGCFTQIF	OR4K17	91	Q8NGC6
FSQYKKPICQFLVES	ATR	926	Q13535
SQARQFKPCIKQINF	FBXL4	186	Q9UKA2
KQCTFRFPSTAIKIQ	FOXK1	186	P85037
CKVFSTPVERKNFLQ	FBXO47	381	Q5MNV8
TQTPALKFKVENFFC	DDHD1	606	Q8NEL9
FPVQVSFVSKKNYCN	ARCN1	466	P48444
PVVNQTVKCLKFSTF	RTTN	161	Q86VV8
KKCTPNAVFNELFVF	SYT4	346	Q9H2B2
SCTVFSNFPVIKNKN	UTP18	506	Q9Y5J1
RFTKNNFFVEKNPTI	USP39	456	Q53GS9
LFYQETLQPFKVCKQ	RGS22	706	Q8NE09
TLQPFKVCKQAQYLF	RGS22	711	Q8NE09
KKQPFVCSSLLQFAR	SUPV3L1	581	Q8IYB8
IFFQPTQKKSVCLFQ	THEM5	131	Q8N1Q8
FKCPVCFTVFVQANK	ZNF521	1256	Q96K83
FCVKFANSFIPKFIT	VPS53	666	Q5VIR6
LIFTFFNIKGQNTKC	XKR9	271	Q5GH70